Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate.

摘要: Abstract 5 patients with visceral leishmaniasis were treated sodium stibogluconate (2 patients) or meglumine antimoniate (3 given intramuscularly at a dose of 10 mg antimony (Sb) per kg body weight daily for 30 d. Blood samples obtained intervals during treatment and blood Sb concentrations measured by anodic stripping voltametry. The pharmacokinetics both drugs remarkably similar, peak approximately mg/litre occurring 2 h after the initial dose. Most was eliminated rapidly, but nadir increased gradually from 0·04-0·08 24 first to 0·19-0·33 30th For drugs, data best described two compartment, three term pharmacokinetic model representing an absorption phase mean half-life 0·85 h, rapid elimination 2·02 slow 76 h. terminal may be related in vivo conversion pentavalent trivalent Sb, which could contribute toxicity associated long-term, high therapy.